June 24, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2025.06.24 09:41:58 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Press Release
For Immediate Distribution

Glenmark Pharmaceuticals Launches TEVIMBRA® in India: Expanding Access to Innovative Immuno-Oncology Treatment for Non-Small Cell Lung Cancer and Esophageal Squamous Cell Carcinoma

Mumbai, India, June 24, 2025: Glenmark Pharmaceuticals Ltd. (Glenmark) a research-led, global pharmaceutical company, launched TEVIMBRA® (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy.

This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases[1]. Similarly, ESCC is the most common histological subtype of esophageal cancer in India[2]. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers.

TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.

"With the launch of TEVIMBRA, Glenmark is delivering on its commitment to transform cancer care in India by making globally benchmarked immunotherapies more accessible," said **Alok Malik**, **President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd.** "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access TEVIMBRA, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers which are difficult to treat. Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients."

We would like to acknowledge BeiGene (now BeOne Medicines) and Pi Health for their studies on Tislelizumab.

About TEVIMBRA® (tiselizumab)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1(PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body's immune cells to detect and fight tumors.

TEVIMBRA is the foundational asset of BeiGene (now BeOne Medicines) solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 35 countries and regions across 70 trials, including 21 registration-enabling studies. TEVIMBRA is approved in 46 countries, and more than 1.5 million patients have been treated globally.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma).

References

1. https://my.clevelandclinic.org/health/diseases/4375-lung-cancer
2. Mangalaparhi et al. Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort. Front Oncol. 2020;10:1457. doi: 10.3389/fonc.2020.01457